Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells

Fig. 7

TRAIL-R2 induced by siCHKA as TAA for retargeting of lymphocyte cytotoxicity by anti-TRAIL-R2/anti-CD3 bispecific antibody. a. Cartoon depicting the retargeting of lymphocyte against siCHKA ex vivo OC cells expressing TRAIL-R2, by anti-TRAIL-R2/anti-CD3 bispecific antibody (bsAb). b. Representative flow cytometry analysis indicating TRAIL-R2 membrane expression in siCHKA and siNT ex vivo patient-derived ascitic tumor cells. Fluorescence index are reported. c. Percentage of growth inhibition of patients-derived ex vivo siCHKA and control OC cells in the presence of anti-TRAIL-R2/anti-CD3 bsAb, lymphocytes alone (PBLs) or their combination; asterisks are referred to a statistically significant difference

Back to article page